The identification of MALT1 as a gene that is perturbed in the B cell neoplasm MALT lymphoma, already more than a decade ago, was the starting point for an intense area of research. The fascination with MALT1 was fueled further by the observation that it contains a domain homologous to the catalytic domain of caspases and thus potentially could function as a protease. Discoveries since then initially revealed that MALT1 is a key adaptor molecule in antigen receptor signaling to the transcription factor NF-κB, which is crucial for lymphocyte function. However, recent discoveries show that this function of MALT1 is not restricted to lymphocytes, witnessed by the ever increasing list of receptors from cells within and outside of the immune system that require MALT1 for NF-κB activation. Yet, a role for MALT1 protease activity was demonstrated only recently in immune signaling and its importance was then further strengthened by the dependency of NF-κB-addicted B cell lymphomas on this proteolytic activity. Therapeutic targeting of MALT1 protease activity might therefore become a useful approach for the treatment of these lymphomas, and additionally, an effective strategy for treating other neoplastic and inflammatory disorders associated with deregulated NF-κB signaling.
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Background
MALT1, a regulator of NF-κB signaling
The Mucosa Associated Lymphoid Tissue lymphoma translocation 1 (MALT1) gene was first identified by virtue of its involvement in the recurrent t(11;18)(q21;q21) chromosomal translocation in the Bcell neoplasm, MALT lymphoma (1) (2) (3) . This translocation creates a fusion oncoprotein consisting of the carboxy terminus of MALT1 linked to the amino terminus of cellular inhibitor of apoptosis 2 (abbreviated as cIAP2 or API2) (Fig. 1A) . MALT1 was noted to contain a putative proteolytic domain that bears similarity to the active site of the caspase family of cysteine proteases (3) (4) (5) . However, structural analyses suggested that, in contrast to caspases, MALT1 would show specificity for substrates with a basic or uncharged amino acid in the P1 position (amino-terminal to the cleavage site). Hence, MALT1 has been classified as a 'paracaspase' to distinguish it from caspases and to recognize its similarity to other 'paracaspase' family members found in zebrafish and Dictyostelium (5) .
The discovery that expression of API2-MALT1 results in constitutive activation of the canonical NF-κB pathway (4, 5) led to numerous investigations of the role of MALT1 as a regulator of the NF-κB family of transcription factors. MALT1 binds to the adaptor protein, BCL10, and synergizes with BCL10 in promoting canonical NF-κB activation (4, 5) . Notably, MALT1 and BCL10 can each be deregulated via the recurrent t(14;18)(q32;q21) and t(1;14)(p22;q32) translocations in MALT lymphoma, respectively, because these translocations bring the MALT1 or BCL10 gene under the control of the Ig-heavy-chain gene enhancer, thus leading to inappropriately enhanced expression (6) . In addition to its "caspase-like" proteolytic domain, MALT1 contains an amino-terminal death domain (DD) and three Ig-like protein-protein interaction domains (Fig. 1A) . BCL10 binds to a region of MALT1 that comprises the DD and first Ig domain, and this interaction induces the oligomerization of MALT1 (4, 7) . MALT1 oligomerization triggers activation of the Inhibitor of kappa B kinase (IKK) complex, leading to phosphorylation dependent-degradation of inhibitor of kappa-Bα (IκBα) and release of transcriptionally active NF-κB dimers, composed primarily of p65(relA) and p50, into the nucleus (Fig. 1B) (4, 8) . In the case of API2-MALT1, API2 moiety-mediated auto-oligomerization allows for constitutive NF-κB activation in the absence of BCL10 (9, 10) , and API2 moiety-mediated recruitment of other NF-κB signaling proteins, such as TRAF2, also contributes to API2-MALT1-dependent NF-κB activation (7, 9, 11 ). The precise mechanism by which MALT1 or API2-MALT1 stimulates IKK activation is not completely understood, but involves recruitment of the ubiquitin ligase, TRAF6, (7, 8) and the TRAF6-directed, K63-linked ubiquitination of several proteins, including IKKγ, BCL10 and MALT1 itself (12) (13) (14) . Early studies suggested that the MALT1 "caspase-like" domain plays a role in NF-κB signaling, as substitution of the predicted active-site cysteine caused a reduction in NF-κB activation by BCL10 / MALT1 or API2-MALT1 (4, 5) .
Analysis of MALT1 knock-out mice revealed that MALT1 plays a critical role in the adaptive immune response by mediating antigen-dependent NF-κB activation in lymphocytes (15, 16) . Biochemical studies then elucidated the specific molecular mechanisms by which MALT1 can be activated in response to antigen receptor engagement. T-cell receptor (TCR) or B-cell receptor (BCR) stimulation induces PKCdependent phosphorylation of CARMA1, a member of the MAGUK family of scaffolding proteins. This phosphorylation induces a conformational change that allows CARMA1 to recruit BCL10/MALT1 to the receptor and form the CARMA1-BCL10-MALT1 (CBM) complex (17, 18) (Fig. 1B) . In the T-cell, formation of the CBM complex is assisted by the coordinated engagement of the CD28 co-receptor which stimulates PI3-kinase dependent phosphorylation of PDK1. Activated PDK1 then stimulates PKCθ and serves to scaffold the TCR with the CBM complex (19, 20) . CBM-mediated recruitment of multiple signaling proteins, such as TRAF6 and the IKK complex, then sets in motion canonical NF-κB activation, leading to cytokine production and cellular proliferation in response to antigen. This precise role for MALT1 is less firmly established in B-cells, as compared to T-cells. While MALT1-deficient T-cells fail to induce IKK-dependent stimulation of NF-κB, proliferate and secrete IL-2 in response to TCR stimulation (15, 16) , the nature of the relationship between BCR stimulation, MALT1-dependent NF-κB signaling, and B-cell activation remains less well understood. Recent studies suggest that MALT1 may be specifically required only for activation of the c-Rel NF-κB subunit, but not essential for IKK recruitment or activation after BCR engagement (21) . In addition to its role in lymphocyte antigen receptor signaling, MALT1 has now been shown to have a critical function downstream of a variety of other cell surface receptors, both within and outside of the immune system (Table 1) . For example, MALT1 mediates BAFF-dependent antiapoptotic gene induction in marginal zone B-cells (22) and IgE FcεRI receptor-mediated secretion of TNFα and IL-6 in mast cells (23) .
In macrophages, MALT1 has been implicated in mediating NF-κB activation downstream of the innate immune / pattern recognition receptors TLR4 and Dectins-1 and -2 (24) (25) (26) , and in natural killer cells, MALT1 operates downstream of multiple ITAM-coupled receptors (27) .
Together, these studies demonstrate that MALT1 plays a significant and complex role in multiple aspects of immunity.
Moreover, recent studies reveal that the MALT1-containing CBM complex also plays a role downstream of G protein-coupled receptors (GPCRs) in a variety of non-immune cell types. In these cases, GPCR-dependent PKC activation triggers the assembly of a CBM complex containing CARMA3, a homolog of CARMA1 that is expressed in cells outside of the hematopoietic system (Fig. 1B) . Thus far, evidence suggests that MALT1 plays a critical role in mediating NF-κB activation downstream of the GPCRs for lysophosphatidic acid (LPA), angiotensin II (Ang II), CXCL8/IL-8, CXCL12/SDF-1α and thrombin (28) (29) (30) (31) (32) .
As a mediator of GPCR-dependent signaling, MALT1 may play a critical role in the pathophysiology of NF- 
MALT1 is a protease
Despite early recognition of the structural similarity between the MALT1 'paracaspase' and the caspase family of cysteine proteases, attempts to demonstrate MALT1 protease activity were initially unsuccessful (5, 35) . Several years later, the MALT1-binding partner, BCL10, and the ubiquitin editing protein, A20, were identified as MALT1 proteolytic substrates . In both cases, mapping of the specific site of cleavage demonstrated that, in contrast to caspases which cleave their substrates after a negatively charged Asp residue, MALT1 cleaves protein substrates after a positively-charged Arg residue (36, 37) .
This finding was consistent with predictions that had been made years earlier, based on the amino acid composition of the presumed substrate recognition pocket (5). MALT1-mediated BCL10 cleavage is induced following stimulation of the TCR or BCR, and cleavage occurs at a single site five amino acids from the carboxy-terminal end of the protein, between Arg228 and Thr229. Interestingly, BCL10 cleavage is not required for antigen-dependent NF-κB activation, but may play a role in integrin-mediated T-cell adhesion (Fig. 1B) (36) . A20, a ubiquitin editing enzyme that negatively regulates NF-κB, possesses dual functions: the enzyme removes K63-linked polyubiquitin from its substrates, and can then catalyze K48-linked polyubiquitination, thus targeting its substrates for proteasome-mediated degradation (38) . In T-cells, A20 inhibits antigen receptor-mediated NF-κB activation, likely via its ability to remove K63-linked polyubiquitin chains from multiple substrates, including TRAF2, TRAF6, receptor interacting protein 1 (RIP1), BCL10, the IKK-γ subunit and even MALT1 itself (37, 39, 40) . A20 deficiency protects B-cells from cell death, and A20 is frequently inactivated in B-lineage lymphomas, indicating its role as a critical tumor suppressor (41) (42) (43) . In response to TCR or BCR stimulation, MALT1 proteolytically cleaves human A20 after Arg439, thereby separating the deubiquitinase (DUB) domain from the C-terminal zinc finger substrate-interaction / ubiquitin ligase domain, and this cleavage results in loss of A20's NF-κB inhibitory function (37) (Fig. 1A) . It is speculated that separation of the N-terminal DUB domain from the C-terminal substrate interaction domain prevents the removal of K63-linked polyubiquitin from A20 substrates, thereby preserving activating ubiquitination events and promoting NF-κB activity ( amplifies the degree of NF-κB-dependent gene expression. A later report demonstrated that two other potential MALT1 cleavage sites are present within A20, and cleavage by MALT1 induces the cytosolic release of an N-terminal A20 fragment, suggesting that changes in cellular compartmentalization may also be a mechanism by which MALT1-mediated cleavage alters A20 activity (44) .
A third MALT1 proteolytic substrate, CYLD, was recently identified (45) . Like A20, CYLD is a tumor suppressor deubiquitinating enzyme that negatively regulates NF-κB (40) . CYLD was originally identified as a gene that is mutated in familial cylindromatosis, a disorder in which mutations resulting in truncated CYLD proteins lacking DUB activity are associated with benign tumors of the skin adnexa (46) . Subsequently, CYLD has been more broadly implicated as a tumor suppressor for multiple types of cancer including the Bcell neoplasm, multiple myeloma (40) . Interestingly, CYLD de-ubiquitinates many of the same substrates as A20, including TRAF2, TRAF6, RIP1 and IKKγ (40) . In response to TCR stimulation, MALT1 cleaves CYLD after Arg324 (Fig. 1B and Table 1) . Surprisingly, a non-cleavable CYLD mutant does not impair TCRdependent canonical NF-κB activation, but does block activation of JNK, a critical step in TCR-induced stimulation of multiple transcription factors and production of IL-2 (45).
A new study now suggests that in addition to its role in adaptive immunity, MALT1 protease activity also contributes to the innate immune response by mediating Dectin-dependent signaling in human primary dendritic cells (DCs) (26) . Dectin -1 and -2 are C-type lectins that interact with the carbohydrate structures present in the cell wall of fungi and thereby play an important role in anti-fungal immune responses. Circulating IL-2 and T-cell IL-2 receptor α (IL-2Rα) are present only at low concentrations under basal conditions, but following TCR activation, expression of IL-2Rα is induced along with IL-2, forming an autocrine/paracrine signaling loop that promotes T-cell proliferation (58) . Thus, blocking IL-2 signaling is potentially a powerful approach for immunosuppressive therapy. Indeed, IL-2Rα blockers have been used with some success in preventing organ transplant rejection, managing specific autoimmune conditions and treating adult T-cell leukemia (59) . It will be of great interest to determine whether blockade of MALT1 protease-dependent IL-2 production can be achieved in vivo and if such an approach is effective in treating these disorders.
One important caveat, however, is that IL-2 also plays a critical role in the thymic development of regulatory T (Treg) cells and self-tolerance. Somewhat paradoxically, failure to produce normal IL-2 upon TCR activation is associated with severe autoimmune disease in mice and systemic lupus erythematosus in humans (60) . It is thought that precise control of both systemic and local amounts of IL-2 is required to achieve the necessary balance between T effector activity and Treg function. Genetic ablation of BCL10 or CARMA1 in mice is associated with impaired Treg differentiation, suggesting that MALT1 likely plays a role in this process as well (61) . It will be important to investigate how inhibition of MALT1 protease-dependent IL-2 production might affect this critical balance.
Blockade of MALT1 protease activity has recently been found to also inhibit the production of IL-1β against extracellular bacteria and fungi, Th17 cells are thought to play a detrimental role in the development of a variety of inflammatory disorders, including atopic dermatitis, psoriasis, multiple sclerosis, rheumatoid arthritis and others, and blockade of Th17 signaling has shown promise as an effective treatment approach in mice and humans with these conditions (62) . There may be a future role for therapeutic inhibition of MALT1 protease in the treatment of these disorders, but how blocking MALT1 protease activity would disrupt the delicate balance between Th17-mediated host defense and Th17-mediated autoimmunity remains to be investigated.
Finally, in addition to its potential role in B-cell lymphoma and inflammatory disorders, deregulated MALT1 is also implicated as contributing to varied disease processes linked to inappropriate GPCR stimulation. For example, recent studies suggested that MALT1 is required for ovarian and oral squamous cancer cell invasion in response to GPCR stimulation by LPA and CXCL12, respectively (31, 33) . However, whether MALT1 proteolytic activity is stimulated following ligation of the LPA receptor or CXCR4, or whether cleavage of specific MALT1 proteolytic substrates contributes to GPCR-induced malignant phenotypes has not yet been addressed. Similarly, several reports implicate MALT1 in mediating GPCR-induced endothelial dysfunction and atherosclerosis (30, 32, 34) , but the role of MALT1 protease activity in these processes has not been investigated. The contribution of MALT1 protease activity to GPCR-dependent signaling, both in normal physiology and in disease, is certain to become a topic of intense investigation.
Concluding Comments
Thus far, only peptide inhibitors of the MALT1 protease, z-VRPR-fmk and Ac-LSSR-CHO, have been reported (36, 54) , and it is not yet known if pharmaceutically suitable compounds that can inhibit MALT1 protease activity in vivo and can be safely administered to patients will be identified. Only three proteolytic substrates for wild-type MALT1 (BCL10, A20 and CYLD) and one unique substrate for API2-MALT1 (NIK) have been identified so far, and little information is available regarding the structural requirements for MALT1 protease interaction with its substrates. To date, MALT1 protease activity has been implicated in three distinct aspects of NF-κB signaling: canonical NF-κB signaling in T-cells, c-Rel (26, 37, 51, 54) . In addition, MALT1-mediated cleavage of BCL10 and CYLD in Tcells have been implicated in contributing to integrin-mediated adhesion and JNK signaling, respectively (36, 45) . Clearly, much remains to be learned in order to determine if targeting MALT1 protease activity will represent a viable therapeutic approach for specific B-cell lymphomas or other diseases.
Several features of the MALT1 protease suggest that it could potentially represent a promising new drug target. First, unlike most proteins, which belong to a family of structurally and functionally related proteins, MALT1 is the only human paracaspase (5). This suggests that designing pharmaceuticals that specifically target MALT1 and do not cause unwanted off-target effects by interacting with other related proteins, may be possible. Second, MALT1 deficient animals are fertile and fairly healthy (15, 16) , suggesting that inhibition of MALT1 activity may be tolerable in human patients. Third, although MALT1-deficient T-cells are defective in antigen-receptor-induced cytokine production and proliferation, blockade of MALT1 proteolytic activity only partially inhibits TCR-induced cytokine production by 40-60% (36) . It has been suggested that this partial effect on cytokine production may indicate that the scaffolding function of MALT1 is still preserved when MALT1 enzymatic activity is inhibited. Therefore, the effect of MALT1 protease inhibition on lymphocyte function may be less severe than the effect of MALT1 deficiency and the degree of immune suppression may be acceptable (52) . Fourth, the many investigations described in this review indicate that MALT1 protease activity plays a prominent role in both MALT lymphoma and ABC-DLBCL, and also likely contributes to other neoplastic and inflammatory disorders.
There is some track record of success in pharmacological inhibition of protease activity as a strategy 
successfully with protease inhibitors (64) . Perhaps the MALT1 protease, a protein that was discovered as a target of recurrent chromosomal translocation in MALT lymphoma, will join the ranks of the many proteases that can be successfully targeted for the treatment of human disease. Future studies of MALT1 will hopefully lead to identification of new proteolytic substrates, elucidation of the structural requirements for MALT1 catalytic activity, further characterization of the biologic role of MALT1, and improved treatment strategies for B-cell lymphoma and beyond. 
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